Physician
Infectious Disease
Dr. Peter J. Ruane, MD
|
|
Give Review
Dr. Peter J. Ruane is an expert in the field of Infectious Disease. He over the years received 1 awards: "CMS Meaningful Use Stage 1 Certification". Peter Ruane is a published doctor and has 42 publications published. The lastest was: 'Ulcerative and plaque-like tracheobronchitis due to infection with Aspergillus in patients with AIDS.' He accepts Medicare payments and is registered with Medicare.gov.
Publications
- Sofosbuvir plus ribavirin for the treatment of chronic genotype 4 hepatitis C virus infection in patients of Egyptian ancestry.
- Phase I/II study of the pharmacokinetics, safety and antiretroviral activity of tenofovir alafenamide, a new prodrug of the HIV reverse transcriptase inhibitor tenofov...
- Simplification to rilpivirine/emtricitabine/tenofovir disoproxil fumarate from ritonavir-boosted protease inhibitor antiretroviral therapy in a randomized trial of HIV...
- Antiviral activity, safety, and pharmacokinetics/pharmacodynamics of tenofovir alafenamide as 10-day monotherapy in HIV-1-positive adults.
- Ombitasvir, paritaprevir co-dosed with ritonavir, dasabuvir, and ribavirin for hepatitis C in patients co-infected with HIV-1: a randomized trial.
- Safety and efficacy of ombitasvir - 450/r and dasabuvir and ribavirin in HCV/HIV-1 co-infected patients receiving atazanavir or raltegravir ART regimens.
- Spirochete-like organisms in the human gastrointestinal tract.
- Laparoscopic-guided biopsy for diagnosis of hepatic candidiasis.
- Disseminated infection caused by urease-negative Cryptococcus neoformans.
- Ulcerative and plaque-like tracheobronchitis due to infection with Aspergillus in patients with AIDS.
- Comparison of culture, cytotoxicity assays, and enzyme-linked immunosorbent assay for toxin A and toxin B in the diagnosis of Clostridium difficile-related enteric dis...
- A randomized, double-blind comparison of sulbactam/ampicillin and clindamycin for the treatment of aerobic and aerobic-anaerobic infections.
- Ciprofloxacin for eradication of methicillin-resistant Staphylococcus aureus colonization.
- Failure of rapid agglutination methods to detect oxacillin-resistant Staphylococcus aureus.
- Low-dose daily subcutaneous interleukin-2 in combination with highly active antiretroviral therapy in HIV+ patients: a randomized controlled trial.
- Efficacy, safety, and adherence with a twice-daily combination lamivudine/zidovudine tablet formulation, plus a protease inhibitor, in HIV infection.
- Antiviral activity, pharmacokinetics, and dose response of the HIV-1 integrase inhibitor GS-9137 (JTK-303) in treatment-naive and treatment-experienced patients.
- The safety and tolerability of Z-100 in patients infected with HIV-1.
- Lopinavir-ritonavir versus nelfinavir for the initial treatment of HIV infection.
- Tenofovir DF in antiretroviral-experienced patients: results from a 48-week, randomized, double-blind study.
- Once-daily versus twice-daily lopinavir/ritonavir in antiretroviral-naive HIV-positive patients: a 48-week randomized clinical trial.
- Pilot study of once-daily simplification therapy with abacavir/lamivudine/zidovudine and efavirenz for treatment of HIV-1 infection.
- Efficacy and safety of darunavir-ritonavir at week 48 in treatment-experienced patients with HIV-1 infection in POWER 1 and 2: a pooled subgroup analysis of data from ...
- HIV-1 protease mutations and protease inhibitor cross-resistance.
- Evaluation of efficacy, safety, pharmacokinetics, and adherence in HIV-1-infected, antiretroviral-naïve patients treated with ritonavir-boosted atazanavir plus fixed-d...
- Impact of switching virologically suppressed, HIV-1-infected patients from twice-daily fixed-dose zidovudine/lamivudine to once-daily fixed-dose tenofovir disoproxil f...
- Randomized, phase 2 evaluation of two single-tablet regimens elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate versus efavirenz/emtricitabine/tenofov...
- A 48-week pilot study switching suppressed patients to darunavir/ritonavir and etravirine from enfuvirtide, protease inhibitor(s), and non-nucleoside reverse transcrip...
- EB1 is required for spindle symmetry in mammalian mitosis.
- Similar efficacy of raltegravir when used with or without a protease inhibitor in treatment-experienced patients.
- Pharmacokinetics of once-daily etravirine without and with once-daily darunavir/ritonavir in antiretroviral-naive HIV type-1-infected adults.
- In vitro activity of daptomycin against multidrug-resistant Staphylococcus aureus and S. aureus with known virulence factors, including community-acquired methicillin-...
- Efficacy and safety of etravirine (TMC125) in patients with highly resistant HIV-1: primary 24-week analysis.
- Plasma amprenavir pharmacokinetics and tolerability following administration of 1,400 milligrams of fosamprenavir once daily in combination with either 100 or 200 mill...
- Compact quadruple therapy with the lamivudine/zidovudine combination tablet plus abacavir and efavirenz, followed by the lamivudine/zidovudine/abacavir triple nucleosi...
- Risk factors for community-associated methicillin-resistant Staphylococcus aureus skin infections among HIV-positive men who have sex with men.
- What's next? Treatment options when the first antiretroviral regimen fails virologically or is not tolerated, Part 2.
- What's next? Treatment options when the first antiretroviral regimen fails virologically or is not tolerated, Part 1.
- New nucleoside/nucleotide backbone options: a review of recent studies.
- K65R-associated virologic failure in HIV-infected patients receiving tenofovir-containing triple nucleoside/nucleotide reverse transcriptase inhibitor regimens.
- Pharmacodynamic effects of zidovudine 600 mg once/day versus 300 mg twice/day in therapy-naïve patients infected with human immunodeficiency virus.
Schools
University College At Dublin National University Of Ireland
St Vincents Hospital
Mayo Foundation For Med Education and Research
Wadsworth Va Med Center
Doctors Specialties
- Infectious Disease Medicine
- Infectious Disease
Accepted Insurances
Awards
- CMS Meaningful Use Stage 1 Certification
Education
-
VA Greater Los Angeles Healthcare System -
Mayo School of Graduate Medical Education -
University College of Dublin National Univ SOM
Hospital
-
Cedars-Sinai Medical Center
Drug Facts
| NPI NUMBER | 1467640953 | |
| NPPES Provider LastName | RUANE | |
| NPPES Provider FirstName | PETER | |
| NPPES Provider ZIPCode | 900364667 | |
| NPPES Provider State | CA | |
| Specialty Description | Infectious Disease | |
| Total Claim Count | 3841.0 | |
| Distinct Opioid Count | 1.0 | |
| Opioid Claim Count | 12.0 | |
| Percent Opioid Claims | 0.31 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1467640953 |
| Last Name Of The Provider | RUANE |
| First Name Of The Provider | PETER |
| View All |
Similar Doctors
|
Dr. Catherine Chien, MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Phillip C. Zakowski, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Made Sutjita, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Joanna M. Schaenman, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Jong T. Huang, MD
This Doctor is OpenDoctor Recommended.
|
|
Dr. Joseph M. Nussbaum, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Francoise Kramer, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Annette T. Nitta, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Atul Kothari, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Townson Tsai, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Obiamiwe C. Umeh, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Ardis A. Moe, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Parveen K. Kaur, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Rachel S. Zabner, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Jennifer A. Fulcher, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Maxine E. Liggins, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Leo L. Li, MD
This Doctor is OpenDoctor Recommended.
|